Healthcare / BiotechnologyKOSDAQ
$1121.00
-22.00 (-1.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-14.9B · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$33.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-62.8%
↓Gross Margin
-40.9%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-51.5%
FCF CAGR
—
FCF margin
-6543.4%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $227.8M · net income $-15.53B · FCF $-14.91B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $227.8M | $227.8M | $17.7M | $215.3M | $2.00B |
| Net Income | $-15.53B | $-15.53B | $-14.90B | $-12.40B | $-10.67B |
| EBITDA | $-14.27B | $-14.27B | $-13.65B | $-11.56B | $-10.13B |
| EPS | -481.00 | -481.00 | -486.30 | -476.63 | -467.84 |
| Gross Margin | -40.9% | -40.9% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -6952.9% | -6952.9% | -85523.5% | -6145.5% | -551.5% |
| Net Margin | -6816.3% | -6816.3% | -84176.3% | -5762.3% | -533.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Current Ratio | 9.30 | 9.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.91B | $-14.91B | $-17.30B | $-14.94B | $-8.14B |
| Returns | |||||
| ROE | -62.8% | -62.8% | -93.1% | -65.3% | -36.5% |
| Valuation | |||||
| P/B | 1.46 | 1.46 | 7.53 | 4.90 | 5.88 |
| Growth & Yield | |||||
| Revenue Growth | 1186.7% | 1186.7% | -91.8% | -89.2% | — |
| EPS Growth | 1.1% | 1.1% | -2.0% | -1.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-486.30 → -481.00
Residual
-60.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.